Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 24, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Cantor Global Healthcare Conference on October 1, 2018 ,
View HTML
Toggle Summary ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 24, 2018-- ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence , President and Chief Operating Officer, Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, and Marc Schegerin, Senior Vice President, Strategy,
View HTML
Toggle Summary Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)
BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 13, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation to miransertib (ARQ 092) for the treatment of PIK3CA-Related Overgrowth Spectrum (PROS), a group of related,
View HTML
Toggle Summary ArQule to Participate in Citi’s 13th Annual Biotech Conference on September 6, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 30, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , CEO, Peter Lawrence , President and COO, Brian Schwartz , CMO and Head of R&D and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will
View HTML
Toggle Summary ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 30, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , CEO, and Dr. Brian Schwartz , CMO and Head of Research and Development, will participate in investor meetings and scientific panel discussions at the B.
View HTML
Toggle Summary ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the 20 th Annual Rodman & Renshaw Global Investment Conference
View HTML
Toggle Summary ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
Data Support ARQ 531 as a Potential First- and Best-In-Class Reversible BTK Inhibitor, with the Potential to Address Emerging Resistance to Irreversible BTK Inhibitors BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 13, 2018-- ArQule, Inc. (Nasdaq:ARQL), today announced the publication of preclinical
View HTML
Toggle Summary ArQule Reports Second Quarter 2018 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2018. For the quarter ended June 30, 2018 , the Company reported net income of $5,156,000 or $0.05 per
View HTML
Toggle Summary ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 18, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 13, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,650,000 shares at the
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.